Characteristic | N (%)/mean (SD)/median (Q1; Q3) |

Sex, female | 440 (51.9) |

Age, years | 61 (54; 67) |

BMI, kg/m^{2} | 26.2 (24.0; 29.5) |

Waist circumference, cm | 94.5 (85.9; 103.1) |

HbA1c, mmol/mol | 37 (34; 44) |

Glucose metabolism status | |

Normal | 475 (56.1) |

Pre-diabetes | 118 (13.9) |

Type 2 diabetes | 252 (29.8) |

Other diabetes types | 2 (0.2) |

Total cholesterol, mmol/L | 5.1 (1.1) |

Triglycerides, mmol/L | 1.2 (0.9; 1.7) |

eGFR, mL/min/1.73 m^{2} | 84.1 (73.3; 93.1) |

Hypertension | 581 (68.6) |

History of CVD | 162 (19.2) |

Smoking | |

Never | 324 (38.3) |

Former | 397 (46.9) |

Current | 125 (14.8) |

Alcohol consumption* | |

None | 187 (22.1) |

Low | 469 (55.4) |

High | 190 (22.5) |

Glucose-lowering drugs | 191 (22.5) |

Lipid-lowering drugs | 304 (35.9) |

Antihypertensive drugs | 334 (39.4) |

NSAIDs | 74 (8.7) |

NCV | |

Tibial nerve, m/s | 43.4 (4.9) |

Sural nerve, m/s | 47.6 (5.6) |

Peroneal nerve, m/s | 45.4 (4.7) |

Sural SNAP amplitude (µV) | 10.6 (6.7) |

Continuous data are given as mean (SD) or median (IQR). Categorical variables are given as numbers and percentages (%).

Missing values: sex (n=3); age (n=3); BMI (n=3); waist circumference (n=3); HbA1c (n=3); glucose metabolism status (n=3); total cholesterol (n=3); triglycerides (n=3); hypertension (n=3); history of CVD (n=5); smoking (n=4); alcohol consumption (n=4); glucose-lowering drugs (n=3); lipid-lowering drugs (n=3); antihypertensive drugs (n=3); NSAIDs (n=3); tibial NCV (n=79); sural NCV (n=242); peroneal NCV (n=35); sural SNAP amplitude (n=235).

Missing values were excluded from percentage calculations and from calculations of mean (SD) or median (IQR).

*None defined as 0 glasses/week; low defined as ≤7 glasses/week for women and ≤14 glasses/week for men; high defined as >7 glasses/week for women and >14 glasses/week for men.

BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; NCV, nerve conduction velocity; NSAIDs, nonsteroidal anti-inflammatory drugs; SNAP, sensory nerve action potential.